IEM Innovation Simplifies Risk Management for High Blood Pressure - PWV an Emerging Predictor

Food and Healthcare Press Releases Monday November 10, 2014 08:32
STOLBERG, Germany--10 Nov--PRNewswire/InfoQuest

The individual risk of stroke, kidney failure and heart attack is the decisive factor over whether to start treatment for high blood pressure or increased cholesterol. The risk can be identified at any early stage by measuring the pulse wave velocity (PWV).

IEM - based in Stolberg/Germany - will present the clinically validated PWV system, "Measuring blood pressure and PWV in one", at Medica 2014.

Scientific data shows that the PWV is an independent predictor for cardiovascular events and is significantly superior to simply evaluating traditional risk factors, e.g. increased blood pressure or cholesterol or risk assessment based on the Framingham risk score.

The basic principle of the innovative PWV test method is the combination of blood pressure measurement and pulse wave analysis. PWV is considered the gold standard in arterial stiffness evaluation. It is well known that the stiffer the arteries, the greater the risk of cardiovascular diseases.

The benefit to patients and medical practitioners is the differentiation between vascular health and cardiovascular risk. The advantage is that by measuring the upper-arm blood pressure and PWV in one, a patient can be classified into "low risk" or "very high risk". This provides to the doctor a quick and solid basis for taking a decision on treatment.

The first comprehensive validated test system with the upper-arm cuff is the Mobil-O-Graph(R), which was validated against invasive catheterisation under very strict conditions.
Visit IEM GmbH at Medica from 12th - 15th November 2014 in Hall 9, Stand C68. Have your blood pressure pulse wave analysis performed.
Contactaddress for complete article and editing
I.E.M. GmbH
Cockerillstr. 69
D-52222 Stolberg
Tel: +49-2402-95-000
Fax: +49-2402-95-00-11
Source: I.E.M. GmbH

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics